Campaigns are only as durable as the systems that support them
Across Nigeria, a coordinated effort to vaccinate 58 million people against measles, rubella, and HPV has revealed something quietly significant: a nation long doubted for its health infrastructure demonstrated that its systems, when properly resourced, can rise to the scale of its need. Awareness of the MR vaccine climbed from 7 to 61 percent in the span of a year, and cities like Lagos recorded coverage rates that rival far wealthier nations. Yet the deeper question the campaign leaves behind is not whether Nigeria can mobilise — it has answered that — but whether it possesses the institutional patience to sustain what a single campaign moment cannot permanently secure.
- Measles, rubella, and cervical cancer have quietly claimed Nigerian lives for decades, and the urgency of the vaccine rollout was inseparable from the weight of that accumulated, preventable loss.
- When campaigns launched, awareness of the MR vaccine stood at just 7 percent — a near-invisible foundation from which to build public trust and demand across a nation of extraordinary scale and diversity.
- More than 1,300 community champions, coordinated federal-state-local leadership, and advocacy partnerships transformed hesitancy into participation, pushing Lagos to 96 percent MR coverage and 76 percent of its HPV target for adolescent girls.
- Beneath the headline numbers, healthcare workers struggled with data entry, monitoring systems faltered, schools and clinics operated in isolation, and community engagement dropped sharply once the campaign intensity faded.
- Nigeria now faces the harder work: embedding these vaccines into routine care, repairing data infrastructure, sustaining community trust, and ensuring that the girl vaccinated today receives her second dose tomorrow.
Nigeria's measles-rubella and HPV vaccine campaigns reached 58 million people — a scale that challenged the assumption that the country's health infrastructure was too fragile to deliver. What the rollout revealed was more precise: when properly resourced and coordinated, the system worked. It did not resolve Nigeria's health challenges. But it proved the machinery to address them was real.
Measles and rubella have disabled and killed Nigerian children for generations. Rubella carries a particular hidden toll among pregnant women, raising the risk of miscarriage and birth defects. Cervical cancer, driven almost entirely by HPV, claims thousands of Nigerian women annually — preventable deaths the country had the tools to stop but lacked the coordination to prevent at scale. These campaigns represented a decision to finally act.
Awareness of the MR vaccine stood at just 7 percent in early 2025. By the time post-campaign surveys were conducted in 2026, that figure had risen by 61 percent — a transformation driven by sustained messaging, over 1,300 community advocates, and visible political leadership. In Lagos, vaccination teams reached 150,656 adolescent girls for HPV and achieved 96 percent MR coverage among target-age children. These were not marginal gains. They were the difference between a vaccine stored in a cold chain and a vaccine protecting a life.
Yet the campaigns also exposed what lay beneath the surface. Healthcare workers struggled to record data accurately. Monitoring officers faced technical barriers uploading to national platforms. Schools and health facilities operated in silos. Community engagement fell sharply after the initial push. The machinery that had worked for a campaign moment was not yet built to sustain routine coverage.
The path forward is clear, though it demands patience. MR and HPV vaccines must be embedded in routine immunisation systems — integrated with maternal health weeks, school health programmes, and polio platforms. Data infrastructure must be strengthened. Dedicated vaccination teams must be built. Community engagement must be kept alive through adolescent champions, school-based education, and sustained coalitions of women leaders and traditional authorities. Nigeria has proven it can mobilise at scale. Whether it can sustain that momentum is the question that now defines the work ahead.
Nigeria's measles-rubella and HPV vaccine campaigns reached 58 million people across the country, a scale that surprised many observers who had grown accustomed to thinking of the nation's health infrastructure as fragile. What the rollout actually demonstrated was something more nuanced: the country's immunisation systems, when properly resourced and coordinated, could deliver. The campaigns did not solve Nigeria's health challenges. But they proved the machinery existed to address them.
Measles and rubella have killed and disabled Nigerian children for decades. Rubella in particular carries a hidden toll—pregnant women infected with the virus face severe risks of miscarriage and birth defects. Cervical cancer, driven almost entirely by HPV infection, claims thousands of Nigerian women each year, many of them young. These are not abstract statistics. They represent preventable deaths and suffering that the country had the tools to stop but lacked the coordination to deploy at scale. The introduction of MR and HPV vaccines represented a decision to finally act on that capability.
The foundation for success already existed, though few outside the health sector recognized it. Years of investment in primary healthcare infrastructure, cold chain expansion, workforce training, and data systems had quietly accumulated. When the campaigns began, they did not start from zero. They built on something real. Yet awareness of the vaccines themselves was nearly nonexistent. A survey in March 2025 found that only 7 percent of Nigerians had heard of the MR vaccine. Hesitancy was real. Competing priorities consumed people's attention. In some areas, political support remained muted. The path forward was not obvious.
Advocacy changed the equation. By June 2025, awareness of MR had climbed to 24 percent. In high-priority local government areas, the figure rose further. By March 2026, post-campaign surveys recorded a 61 percent increase in awareness overall—a transformation driven by sustained messaging, community champions, and visible leadership from governors and health commissioners. The campaigns mobilized more than 1,300 community advocates. In Lagos alone, vaccination teams reached 150,656 adolescent girls for HPV vaccination, capturing 76 percent of the annual target. MR coverage in the same state hit 96 percent among children in the target age group. These were not marginal gains. They were the difference between a vaccine sitting in a cold chain and a vaccine protecting a child.
But the campaigns also exposed the fragility beneath the surface. Healthcare workers struggled to record vaccination data accurately. Monitoring officers faced technical barriers uploading information to the District Health Information Software 2, the national data platform. Schools and health facilities operated in silos, missing eligible populations. Outreach activities were not consistently planned into microplans. Some facilities lacked dedicated vaccination teams. After the initial mass push, community engagement declined sharply. The machinery that had worked for a campaign moment was not yet built to sustain routine coverage. For HPV vaccination in particular, maintaining uptake among adolescent girls requires continuous trust-building and access, not episodic bursts of activity.
What Nigeria's experience revealed was a paradox: campaigns are only as durable as the systems that support them. Strong federal, state, and local coordination had anchored the rollout. Pathfinder International and C-WINS worked closely with the National Primary Health Care Development Agency, civil society groups, and community leaders. This coalition had power. But the same coalition could not guarantee that a girl vaccinated in March 2026 would receive her second dose on schedule, or that a child's vaccination record would be accurately entered into the national system. The campaigns proved the country could mobilize at scale. They did not yet prove it could sustain.
The path forward is now clear, though it demands sustained commitment. MR and HPV vaccines must be fully embedded in routine immunisation systems, not treated as special projects. This means integrating HPV vaccination into primary healthcare services and aligning it with existing platforms—maternal and child health weeks, polio campaigns, school health programs. It means training healthcare workers to use data systems reliably and giving monitoring officers the technical support to upload information consistently. It means building dedicated vaccination teams and strengthening the links between schools, health facilities, and community structures so that no eligible adolescent falls through the gaps. It means keeping community engagement alive through school-based education, adolescent champions, and sustained coalitions of women leaders, social media influencers, and traditional authorities. Above all, it means the government, civil society, and development partners must deepen collaboration and guarantee the resources to maintain what has been built. Nigeria has proven it can deliver at scale. The question now is whether it will sustain.
Citações Notáveis
Campaigns are only as strong as the systems that underpin them. Nigeria's MR and HPV experience revealed both the power of coordinated leadership and the vulnerabilities of weak linkages.— Analysis from campaign review
A Conversa do Hearth Outra perspectiva sobre a história
Why does a vaccine campaign that reaches 58 million people still feel incomplete?
Because reaching people once is not the same as protecting them over time. A campaign creates momentum, visibility, political will. But routine systems—the quiet infrastructure that delivers vaccines year after year—that is harder to build. Nigeria proved it could mobilize. It has not yet proven it can sustain.
What broke down after the initial push?
Community engagement dropped sharply. Healthcare workers struggled to record data accurately. Schools and health facilities were not talking to each other. The machinery that worked for a moment was not designed for the long term. A girl vaccinated in March might not get her second dose on schedule because there was no system ensuring she was tracked and reminded.
The awareness numbers are striking—from 7 percent to 61 percent. How did that happen?
Sustained advocacy. More than 1,300 community champions, visible leadership from governors and health commissioners, partnerships between government and civil society groups. It was not one advertisement. It was a coalition working continuously, building trust, answering questions, showing up in communities.
But awareness and uptake are different things.
Exactly. Awareness opened the door. But uptake required access—vaccination teams showing up at schools, health facilities being open and stocked, data systems working so that follow-up doses could be scheduled. In Lagos, the infrastructure was stronger, so coverage hit 96 percent for MR. In other areas, it was lower. The gaps reveal where the routine systems are still weak.
What does integration into routine systems actually mean?
It means HPV vaccination becomes part of what a health facility does every week, not a special campaign. It means a girl's vaccination record is entered into the national database reliably, so she can be tracked for her second dose. It means schools and clinics coordinate so adolescents are reached consistently. It means the coalition of advocates stays active, not just during campaigns but year-round.
Is there a risk Nigeria loses this momentum?
Yes. Campaigns create energy. But energy fades if the systems underneath do not hold. That is why the next phase is critical. If MR and HPV are not fully integrated into routine immunisation now, if data systems are not strengthened, if community engagement is not sustained, the gains will erode. The choice is to act decisively or watch the progress slip away.